Trial · NCT02002208

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

NCT02002208, Phase 2, Completed, Atopix Therapeutics, Ltd.; results first posted 2016-12-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of OC000459 on Moderate to Severe Atopic Dermatitis. Trials, record NCT02002208. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02002208

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of OC000459 on Moderate to Severe Atopic Dermatitis
NCT number: NCT02002208
Status: Completed
Phases: Phase 2
Enrollment: 142 participants, actual
Lead sponsor: Atopix Therapeutics, Ltd.
Conditions: Atopic Dermatitis
Interventions: OC000459
First posted: 2013-12-05
Last updated: 2018-03-26
Results first posted: 2016-12-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16	EASI was measured at baseline (week 0) and 16 weeks after dosing.	The EASI scoring system uses a defined process to grade the severity of the signs of eczema and the extent affected in four regions of the body: head and neck, trunk, upper extremities and lower extremities. The scale ranges from 0 to 72 and the severity strata for the EASI are as follows: 0 clear; 0.1-1.0 almost clear; 1.1-7.0 mild; 7.1-21.0 =moderate; 21.1-50.0 severe; 50.1-72.0 very severe. When assessing response to therapy a reduction of 7 or more is considered to be clinically meaningful.
Secondary	Rate of Flares	over 16 weeks

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16	EASI was measured at baseline (week 0) and 16 weeks after dosing.	Adjusted mean change from baseline EASI at Week 16	units on a scale	MEAN
SECONDARY	Rate of Flares	over 16 weeks		flares	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16	OC000459 Tablets	-3.8	Standard Error 1.72	units on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16	Placebo Tablets	-6.1	Standard Error 1.71	units on a scale
Rate of Flares	OC000459 Tablets	2.879	Standard Deviation 2.8679	flares
Rate of Flares	Placebo Tablets	2.646	Standard Deviation 4.7922	flares

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	OC000459 Tablets	69
Overall Study	STARTED	Placebo Tablets	70
Overall Study	COMPLETED	OC000459 Tablets	32
Overall Study	COMPLETED	Placebo Tablets	30
Overall Study	NOT COMPLETED	OC000459 Tablets	37
Overall Study	NOT COMPLETED	Placebo Tablets	40

Source ClinicalTrials.gov

Adverse events74

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	OC000459 Tablets	15	70
other	Headache	Nervous system disorders	Placebo Tablets	15	71
other	Nasopharyngitis	Infections and infestations	OC000459 Tablets	9	70
other	Nasopharyngitis	Infections and infestations	Placebo Tablets	15	71
other	Pruritus	Skin and subcutaneous tissue disorders	OC000459 Tablets	6	70
other	Pruritus	Skin and subcutaneous tissue disorders	Placebo Tablets	4	71
other	Herpes simplex	Infections and infestations	OC000459 Tablets	4	70
other	Herpes simplex	Infections and infestations	Placebo Tablets	2	71
other	Nausea	Gastrointestinal disorders	OC000459 Tablets	3	70
other	Nausea	Gastrointestinal disorders	Placebo Tablets	4	71

1 to 10 of 74Source ClinicalTrials.gov

See all 74 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	OC000459 Tablets
Total, all-cause mortality	Placebo Tablets
Total, other adverse events	OC000459 Tablets	52	70
Total, other adverse events	Placebo Tablets	47	71
Total, serious adverse events	OC000459 Tablets	2	70
Total, serious adverse events	Placebo Tablets	6	71

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
OC000459 Tablets vs Placebo Tablets: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02002208

GET https://conductscience.org/api/trials/v1/NCT02002208/events?page=2

API reference For AI assistants